Regulus Therapeutics Inc.
DelistedCIK 1505512fmd_097W90JPZE8Z731S4GDECR9269Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Mar 31, 2025, 58 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 21 | 1 | 0 | 0 | 7 | 10 | 0 | – | – | – |
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | – | – |
| Research and development | 56 | 64 | 53 | 34 | 12 | 15 | 18 | 18 | 21 | 35 |
| Total operating expenses | 76 | 83 | 70 | 47 | 24 | 24 | 28 | 28 | 31 | 50 |
| Operating income | (55) | (82) | (70) | (47) | (17) | (14) | (28) | (28) | (31) | (50) |
| Interest expense | 0 | 1 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 0 |
| Interest and investment income | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 4 |
| Income before taxes | (56) | (82) | (72) | (49) | (19) | (16) | (28) | (28) | (30) | (46) |
| Income tax expense | (0) | (0) | (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (56) | (82) | (72) | (49) | (19) | (16) | (28) | (28) | (30) | (46) |
| Net income | (56) | (82) | (72) | (49) | (19) | (16) | (28) | (28) | (30) | (46) |